Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis.
Sorensen PS, Ross C, Clemmesen KM, Bendtzen K, Frederiksen JL, Jensen K, Kristensen O, Petersen T, Rasmussen S, Ravnborg M, Stenager E, Koch-Henriksen N; Danish Multiple Sclerosis Study Group.
Sorensen PS, et al. Among authors: bendtzen k.
Lancet. 2003 Oct 11;362(9391):1184-91. doi: 10.1016/S0140-6736(03)14541-2.
Lancet. 2003.
PMID: 14568740
Clinical Trial.